Virica - Viral Medicines
Viral Medicines are the Way of the Future. Gene therapies and vaccines save and protect human life. The COVID-19 pandemic highlights the criticality of vaccine development today and into the future. The pandemic also highlights the challenges drug developers and manufacturers face. To achieve meaningful yields of viral medicines, you rely on living cells, grown at scale, in specialized equipment. You need to achieve these yields in tight timeframes. You require effectiveness. Manufacturing complex and effective viral medicines at scale needs to be achieved. How do you increase yield? How do you increase effectiveness?
We understand the barriers holding drug developers and manufacturers back from achieving the potential of your products and services.
Your viral medicines face fundamental manufacturing and therapeutic challenges due to cellular antiviral defenses.
Our proprietary and pioneering Viral Sensitizers (VSE™) unlock your potential to increase yield and effectiveness at better margins. Virica is the first company to develop and commercialize VSEs to solve the real-world challenges facing you in delivering the promise of critical viral medicines.
VSEs are proprietary small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level. VSEs do this by transiently altering cell signaling, which allows the virus to infect, transduce, and replicate better.
We have a library of over 100 VSEs. Each are different from one another, so each attenuate the antiviral defense in different ways. For this reason, VSEs are sometimes more effective in combination. VSEs are applicable in manufacturing and therapeutic settings.
